RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy (BgRT) as a new modality for treating all stages of cancer, today announced eight clinical abstracts evaluating the potential use and utility of its novel technology were accepted for presentation during the American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting, Oct. 23-26, in San Antonio. Additionally, ASTRO will serve as the setting for introducing SCINTIX as the new product name for RefleXion’s flagship BgRT technology and treatment, provided only through the company’s X1 platform.
“We are so pleased to once again have multiple posters and presentations highlighting the potential for our innovative SCINTIX technology in 21st-century radiation oncology practice,” said Shervin ‘Sean’ Shirvani, M.D., M.P.H, chief medical officer at RefleXion. “This body of work highlights the advanced conventional capabilities of the X1 and reveals key future possibilities for SCINTIX technology in which each tumor's unique biology guides its own treatment.”
